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Objectives This study sought to investigate differences in outcome between patients treated with successful strict, failed
strict, and lenient rate control.
Background The RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation) study showed no difference in outcome be-
tween lenient and strict rate control in patients with permanent atrial fibrillation (AF). However, in the strict
group not all patients achieved the pre-defined heart rate target.
Methods The primary outcome was a composite of cardiovascular morbidity and mortality. For the current analysis out-
come events were analyzed from end of the dose-adjustment phase until end of follow-up (median 2.9 years
[interquartile range: 2.4 to 3.0 years]). Of 614 patients, 608 completed the dose-adjustment phase—301 in the
strict (resting heart rate 80 beats/min, and during moderate exercise 110 beats/min) and 307 in the lenient
group (resting heart rate 110 beats/min). In the strict group, 203 of 301 patients achieved the rate control
target, and 98 failed.
Results Heart rate was different after the dose-adjustment phase between the successful strict (72  7 beats/min),
failed strict (86  14 beats/min), and lenient (93  8 beats/min) group (p  0.001) and remained significantly
different during follow-up. The primary outcome was reached in 27 of 203 (14.2% KM estimate) in the success-
ful strict versus 14 of 98 (15%) in the failed strict versus 35 of 307 (12.1%) in the lenient group (p  0.5). The
components of the primary outcome and quality of life were similar in the groups.
Conclusions In patients with permanent AF, successful strict rate control does not improve outcome. Therefore, lenient rate
control might be frontline therapy. (J Am Coll Cardiol 2013;61:741–8) © 2013 by the American College of
Cardiology Foundation
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Rate Control Efficacy in Atrial Fibrillation February 19, 2013:741–8Rate control is frontline therapy
in patients with permanent atrial
fibrillation (AF) (1,2). Evidence
is accumulating that lenient rate
control is a reasonable strategy in
patients with permanent AF.
Post hoc analyses of the AFFIRM study (Atrial Fibrillation
Follow-up Investigation of Rhythm Management) and
RACE (RAte Control versus Electrical cardioversion) study
showed a comparable outcome between patients with per-
manent AF with higher and lower heart rates (3–5). The
RACE II (RAte Control Efficacy in permanent atrial
fibrillation II) trial prospectively evaluated the effect of
lenient versus strict rate control in patients with permanent
See page 749
AF (6) and showed no difference in outcome between the
lenient and strict rate control groups in terms of cardiovas-
cular morbidity, mortality, and quality of life (7,8). How-
ever, not all patients achieved the heart rate target, especially
not in the strict group (7). The inability of achieving the
strict rate control target might have influenced outcome, in
favor of lenient rate control. The current post hoc analysis
evaluates the difference in outcome between patients treated
with successful strict, failed strict, and lenient rate control.
Methods
The RACE II study design. The study design and results
f the RACE II study have been published previously (6,7).
he study was approved by the institutional review boards
f all participating centers, and all patients gave written
nformed consent. Patients were randomized to lenient
resting heart rate 110 beats/min) or strict rate control
resting heart rate 80 beats/min, and a heart rate 110
beats/min during moderate exercise). The primary outcome
was a composite of cardiovascular morbidity and mortality
Randomizatio
n=614 
Strict rate control 
n=303 
Excluded from
current analyse
n=2 
Hospitalization for heart fail
Pacemaker implantation
Successful strict 
n=203 
Failed strict 
n=98 
Figure 1 Study Flow Chart, Randomization, and Success of Rat
Flow chart for randomization and success of rate control.
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence intervalas described previously (7). Patients in the strict group who
failed 1 of the heart rate criteria were classified as failed
strict; the remaining patients were classified as successful
strict rate control. Reasons for failure of strict rate control
could be drug-related adverse events, no or tolerable symp-
toms, or heart rate target unattainable with drugs.
Design of the current analysis. For the current analysis
outcome events in the strict rate control group were ana-
lyzed from end of the dose-adjustment phase (i.e., the
moment the heart rate targets were either achieved or
deemed impossible or unnecessary [due to absence of
complaints] to achieve) until end of follow-up. In the
lenient rate control group the endpoints were analyzed from
9 days after randomization, the mean duration of the
dose-adjustment phase in the lenient group, until end of
follow-up. Patients with a primary outcome event occurring
during the dose-adjustment phase in the strict group and
before 9 days after randomization in the lenient group were
not included in the present analysis.
Quality of life. Quality of life was assessed with the
Medical Outcome Study Short Form-36, University of
Toronto AF Severity Scale, and Multidimensional Fatigue
Inventory-20 as has been described previously (8–12).
Statistical analysis. Baseline descriptive statistics are pre-
sented as mean  SD or median (range) for continuous
variables and counts with percentages for categorical vari-
ables. Differences between groups, in terms of patient
characteristics, were evaluated by one-way analysis of vari-
ance, Kruskal-Wallis test, or chi-square test, depending on
normality and type of data. Differences in quality of life
between the groups were assessed with a general linear
model and a general linear model repeated measures. In all
analyses a value of p  0.05 was considered statistically
significant. Kaplan-Meier analysis was performed to assess
differences in outcome between the 3 groups. Noninferiority
was tested by comparing the upper boundary of the 90%
confidence interval (CI) for the primary outcome (7).
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Rate control achievement during the dose adjustment
phase. In the current analysis 608 patients were included.
Two hundred and three patients had successful strict, 98
had failed strict, and 307 patients had lenient rate control
(Fig. 1). In 25 patients strict rate control failed due to
drug-related adverse events, 52 patients had no or tolerable
symptoms, and in 21 patients the strict heart rate criteria
were unattainable to achieve with drugs.
Patient characteristics. Heart rates were higher in the
failed strict and lenient group as compared with the
successful strict group (Table 1). Median follow-up was
2.9 (interquartile range: 2.4 to 3.0) years. Clinical char-
acteristics were almost comparable between the groups
(Table 2).
After the dose-adjustment phase, more patients in the
lenient group either used no rate control drugs or a beta
Rate Control Targets and Drug Therapy at End of Dose-AdjustmentTable 1 Rate Control Targets and Drug Therapy at End of Dose
Success
Rate-control target or targets achieved
Heart rate at end of dose-adjustment phase, beats/min
Resting heart rate distribution at end of dose-adjustment phase
70 beats/min
70–80 beats/min
81–90 beats/min
91–100 beats/min
100 beats/min
Resting heart rate target achieved
Exercise heart rate target achieved
Mean heart rate, beats/min
Mean duration of exercise with target achieved, s
Holter monitoring
Mean heart rate, beats/min
Max RR interval, s
Visits to achieve rate-control target or targets
Median (interquartile range)
Reason for failure to achieve rate-control target or targets
Drug-related adverse events
No symptoms or symptoms tolerated
Target impossible to achieve with drugs
Rate control medications in use at end of dose-adjustment phase, n (%)
No rate control drugs
Beta blocker alone
Verapamil/diltiazem alone
Digoxin alone
Beta blocker  verapamil/diltiazem
Beta blocker  digoxin
Verapamil/diltiazem  digoxin
Beta blocker  verapamil/diltiazem  digoxin
Dose at the end of the dose-adjustment phase, mg
Beta blocker (adjusted to metoprolol)
Verapamil
Diltiazem
Digoxin*Not all patients performed exercise test due to unexpected physical limitations (e.g., recent surgery) (nblocker alone. Fewer patients in the lenient group used a
combination of drugs and used significantly lower dosages
of beta blockers and verapamil (Table 1).
Primary outcome after dose-adjustment phase. A total of
76 patients (27 of 203 in the successful strict and 14 of 98
in the failed strict group, and 35 of 307 in the lenient group)
reached the primary outcome (Fig. 2, Table 3). The cumu-
lative difference between successful strict and failed strict
was 0.8 (90% CI: 6.6 to 8.2, p for noninferiority 
.02). The cumulative difference between successful strict
nd lenient rate control was 0.2 (90% CI: 7.4 to 3.2, p for
oninferiority 0.001). There was no significant difference
etween the 3 groups, considering the composites of the
rimary outcome, nor was there any difference in all-cause
ortality (Table 3). There was also no difference in primary
utcome when analyzing patients with an ejection fraction
40% (data not shown, p  0.6).
estment Phase
ict Rate Control
203)
Failed Strict Rate Control
(n  98)
Lenient Rate Control
(n  307) p Value
(100) 0 (0) 302 (98.4)
 7 86 14 93 8 0.001
(30.5) 6 (6.1) 1 (0.3) 0.001
(70.0) 19 (19.4) 5 (1.6)
0 38 (38.8) 111 (36.2)
0 20 (20.4) 122 (39.7)
0 15 (15.3) 68 (22.2)
(100) 25 (25.5) 302 (98.4) 0.001
(94.6)* 27 (27.6) — 0.001
 12 112 16 — 0.001
 42 103 47 — 0.049
 10 82 13 — 0.001
 0.5 2.3 0.6 — 0.9
24 255 74 0.001
(1–3) 2 (1–3) 0 (0–0) 0.001
0.001
/0 25/100 0/7
/0 52/100 5/7
/0 21/100 0/7
(0.5) 2 (2.0) 32 (10.4) 0.001
(20.2) 20 (20.4) 131 (42.7) 0.001
(4.9) 6 (6.1) 18 (5.9) 0.9
(2.0) 1 (1.0) 21 (6.8) 0.015
(13.3) 11 (11.2) 12 (3.9) 0.001
(36.5) 38 (38.8) 59 (19.2) 0.001
(10.3) 8 (8.2) 16 (5.2) 0.1
(8.9) 8 (8.2) 3 (1.0) 0.001
 81 165 95 121 78 0.001
 94 233 102 168 60 0.004
 50 207 90 230 87 0.9
 0.07 0.23 0.1 0.19 0.08 0.007Phas-Adju
ful Str
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Rate Control Efficacy in Atrial Fibrillation February 19, 2013:741–8Additional visits, heart rate, left ventricular function, and drug
use during the study. At 1- and 2-year follow-up, more
atients in the successful strict (17.7% and 12.3%, respec-
ively) and failed strict (14.3% and 8.2%, respectively) as
ompared with the lenient (4.6% and 4.2%, respectively)
roup had at least 1 additional visit (p  0.001 and p 
.007 for 1 and 2 years of follow-up, respectively). There
as no difference in additional visits between the successful
trict and failed strict groups.
Heart rates during the study and left ventricular ejection
raction during the study are shown in Table 4. During
ollow-up no significant changes in drug or combination of
rugs occurred in any of the groups, nor were there
ignificant changes in the dosages of the rate control drugs
data not shown).
ymptoms and quality of life. At the end of study fewer
atients in the failed strict group had any symptom of AF
Baseline Characteristics at RandomizationTable 2 Baseline Characteristics at Randomization
Successful Strict Rate Control
(n  203)
Age, yrs 68 8
Male, n (%) 129 (63.6)
Total AF duration (months) 21 (6–59)
Duration permanent AF (months) 3 (1–7)
Hypertension 120 (59.1)
Coronary artery disease 34 (16.8)
Valvular heart disease 42 (20.7)
Chronic obstructive pulmonary disease 33 (16.3)
Diabetes mellitus 20 (9.9)
Lone AF* 3 (1.5)
Previous heart failure hospital stay 25 (12.3)
CHADS2 score† 1.4 1.2
0 or 1 130 (64.0)
2 44 (21.7)
3–6 29 (14.3)
Symptoms 119 (58.6)
Palpitations 60 (29.6)
Dyspnea 80 (39.4)
Fatigue 67 (33.0)
NYHA functional class
I 123 (60.6)
II 69 (34.0)
III 11 (5.4)
Body mass index 29 5
Blood pressure
Systolic 135 17
Diastolic 82 12
Heart rate in rest, beats/min 94 11
Echocardiography parameters, mm
Left atrial size, long axis 46 7
Left atrial volume, ml 72 28
Left ventricular end-diastolic diameter 51 8
Left ventricular end-systolic diameter 36 8
Left ventricular ejection fraction, % 52 12
40% 34 (16.7)Table 5). Neither at study entry nor at study end were there iny significant differences in The Medical Outcome Study
hort Form-36, Multidimensional Fatigue Inventory-20, and
F-severity scale between the groups (Fig. 3). There was no
ffect of the different rate control strategies over time.
iscussion
his analysis of the RACE II study shows no difference in
ardiovascular outcome between successful strict, failed
trict, and lenient rate control in patients with permanent
F. In addition, quality of life was comparable between the
roups at the end of follow-up.
One of the comments on the RACE II study is that
nly 67% of the patients randomized to the strict group
chieved the heart rate targets, as compared with 98% in
he lenient group. The data of the present analysis
onfirm our prior findings that lenient rate control is not
Failed Strict Rate Control
(n  98)
Lenient Rate Control
(n  307) p Value
66 9 68 8 0.1
67 (68.4) 201 (65.8) 0.7
19 (5–68) 16 (6–54) 0.1
2 (1–5) 3 (1–6) 0.2
54 (55.1) 197 (64.2) 0.4
10 (10.2) 65 (21.2) 0.1
18 (18.4) 63 (20.5) 0.9
10 (10.2) 35 (11.4) 0.3
12 (12.2) 36 (11.7) 0.7
3 (3.1) 5 (1.6) 0.8
7 (7.1) 28 (9.1) 0.4
1.4 1.1 1.4 1.0 0.9
64 (65.3) 176 (57.3) 0.3
20 (20.4) 93 (30.3)
14 (14.3) 38 (12.4)
55 (56.1) 169 (55.1) 0.5
22 (22.5) 61 (19.9) 0.1
29 (29.6) 101 (32.9) 0.04
29 (29.6) 85 (27.7) 0.6
69 (70.4) 206 (67.1) 0.1
27 (27.6) 85 (27.7)
2 (2.0) 16 (5.2)
29 4 29 5 0.7
135 15 137 19 0.4
83 9 85 11 0.02
98 15 96 12 0.1
46 8 46 6 0.6
76 26 72 24 0.3
52 8 51 7 0.8
37 9 36 8 0.8
53 13 52 11 0.6
14 (14.3) 43 (15.6) 0.4
Continued on the next pagenferior to strict rate control, not even when the lenient
New Y
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February 19, 2013:741–8 Rate Control Efficacy in Atrial Fibrillationstrategy is compared with patients who were successfully
treated with a strict rate control strategy (1,2,7,13,14).
Instead, the present analysis shows that attempts to
ContinuedTable 2 Continued
Successful Strict Rate C
(n  203)
Rate control medications in use
No rate control drugs 20 (9.9)
Beta blocker alone 93 (45.8)
Verapamil/diltiazem alone 13 (6.4)
Digoxin alone 15 (7.4)
Beta blocker  verapamil/diltiazem 7 (3.5)
Beta blocker  digoxin 26 (12.8)
Verapamil/diltiazem  digoxin 11 (5.4)
Beta blocker  verapamil/diltiazem  digoxin 5 (2.5)
Sotalol or amiodarone 13 (6.4)
Dose, mg
Beta blocker (adjusted to metoprolol) 124 65
Verapamil 180 72
Diltiazem 233 58
Digoxin 0.17 0.06
Other medications in use
ACE inhibitor and/or ARB 94 (46.3)
Diuretic 78 (38.4)
Statin‡ 54 (26.6)
Vitamin K antagonist 200 (98.5)
Aspirin 4 (2.0)
Values are mean  SD or n (%). *Lone atrial fibrillation (AF) was defined as AF in the absence of
the risk of stroke in patients with AF, with scores ranging from 0 to 6, and higher scores indicate
assigned 1 point, and previous stroke or transient ischemic attack is assigned 2 points; the score is
coenzym A reductase inhibitors.
ACE  angiotensin-converting enzyme inhibitor; ARB  angiotensin II receptor blocker; NYHA 
Figure 2 Kaplan-Meier Estimates of Cumulative Incidence of Pr
The numbers at the end of the Kaplan-Meier curves are the estimated cumulativeachieve strict rate control targets are unsuccessful in
one-third of the patients and not necessary. The latter
might not hold for every patient. If patients remain
Failed Strict Rate Control
(n  98)
Lenient Rate Control
(n  307) p Value
7 (7.1) 36 (11.7) 0.5
42 (42.9) 139 (45.3) 0.9
6 (6.1) 17 (5.5) 0.7
9 (9.2) 19 (6.2) 0.6
4 (4.1) 7 (2.3) 0.8
22 (22.5) 53 (17.3) 0.2
3 (3.1) 14 (4.6) 0.8
0 (0.0) 2 (0.7) 0.2
5 (5.1) 20 (6.5) 0.2
115 67 114 71 0.6
215 79 173 77 0.3
160 57 230 87 0.7
0.22 0.06 0.19 0.08 0.1
45 (45.9) 165 (53.8) 0.2
35 (35.7) 134 (43.7) 0.1
20 (20.4) 101 (32.9) 0.1
96 (98.0) 304 (99.0) 0.9
2 (2.0) 4 (1.3) 0.9
ascular disease and extracardiac precipitating causes of AF. †The CHADS2 score is a measure of
er risk; congestive heart failure, hypertension, an age of 75 years or older, and diabetes are each
ted by summing all points for a given patient. ‡Statins were defined as 3-hydroxy-3-methylglutaryl-
ork Heart Association.
y Outcome
nce of the primary outcome at 3 years.ontrol
cardiov
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calculaimar
incide
746 Groenveld et al. JACC Vol. 61, No. 7, 2013
Rate Control Efficacy in Atrial Fibrillation February 19, 2013:741–8symptomatic or a tachycardiomyopathy develops, lower
heart rate targets might be indicated.
In accordance with the AFFIRM study, we also showed
that a strict rate control strategy is time consuming, neces-
sitating more outpatient visits and more combinations and
higher dosages of rate-control drugs (3,7,15). These differ-
ences emphasize the difference in strategy. Although the
dissimilarity in heart rates between the groups was not as
marked as might have been anticipated, strategies to obtain
those heart rates were completely different.
Why was successful strict rate control not associated with an
improved outcome? First, the incidence of heart failure, being
a major concern of a lenient rate control, was not lower during
Cumulative Incidence of Composite Primary Outcome and Its CompTable 3 Cumulative Incidence of Composite Primary Outcome
Successful Strict Rate
Control
(n  203)
Failed Strict Ra
Control
(n  98)
Primary outcome*
Composite primary outcome 27 (14.2) 14 (15.0)
Death from cardiovascular cause 5 (2.7) 6 (6.7)
Cardiac arrhythmic death 1 (0.5) 3 (3.2)
Cardiac nonarrhythmic death 0 2 (2.5)
Noncardiac vascular death 4 (2.2) 1 (1.1)
Heart failure 5 (2.9) 5 (5.8)
Stroke 8 (4.2) 3 (3.2)
Ischemic stroke 7 (3.7) 1 (1.1)
Hemorrhagic stroke 2 (1.2) 2 (2.2)
Systemic embolism 0 0
Bleeding 9 (4.5) 4 (4.6)
Intracranial bleeding 2 (1.0) 1 (1.1)
Extracranial bleeding 7 (3.5) 3 (3.5)
Syncope 2 (1.0) 1 (1.1)
Life threatening adverse effects of
rate control drugs
1 (0.5) 1 (1.0)
Sustained ventricular tachycardia
or ventricular fibrillation
1 (0.5) 0
Implantable cardioverter
defibrillation implantation
1 (0.6) 0
Pacemaker implantation 1 (0.6) 2 (2.1)
Death from any cause† 10 (5.6) 8 (8.9)
Values are n (%) unless otherwise indicated. Composite primary outcome includes first event for e
strict rate control were analyzed from the end of the dose-adjustment phase until end of study. In
dose-titration in the lenient rate control group, until the end of follow-up. *The cumulative incidenc
not a composite of the primary outcome.
CI  confidence interval.
Heart Rate During Follow-Up and Left VentricularEjection Fractio at End of StudyTable 4 Heart Rate During Follow-Up and Left VentricularEjection Fraction at End of Study
Successful Strict
Rate Control
Failed Strict
Rate Control
Lenient
Rate Control
p
Value
Heart rate
1 year 73 10 81 14 85 13 0.001
2 year 74 12 78 12 83 13 0.001
End of study 75 14 78 12 85 13 0.001
Left ventricular
ejection fraction
at end of study
55 11 55 9 54 11 0.4Values are mean  SD.successful strict rate control. Apparently, a heart rate 110
beats/min was low enough to prevent heart failure, being in
line with post hoc analyses of large heart failure trials showing
that beta blockers do not improve outcome in patients with
heart failure and AF (16–18). Second, patients with AF might
need higher heart rates due to loss of the atrial kick and the
irregular ventricular response (19).
There were no differences in quality of life between the 3
rate control groups. Apparently, not only heart rate alone
but also the use of more and higher dosages of rate control
drugs and the underlying disease influence quality of life.
Study limitations. The difference in heart rate between the
groups was not as marked as would have been expected from
the design of the study. However, the strategies to achieve
those heart rates were completely different. Outcome might
Symptoms of AF at End of StudyTable 5 Symptoms of AF at End of Study
Successful Strict
Rate Control
(n  189)
Failed Strict
Rate Control
(n  83)
Lenient Rate
Control
(n  282)
p
Value
Symptoms 97 (51.3) 29 (34.9) 129 (45.7) 0.03
Palpitations 18 (9.5) 8 (9.6) 30 (10.6) 0.9
Dyspnea 62 (32.8) 19 (22.9) 85 (30.1) 0.3
Fatigue 45 (23.8) 17 (20.5) 69 (24.5) 0.7
tsts Components
enient Rate
Control
(n  307)
Hazard Ratio (95% CI)
Failed vs. Successful Successful vs. Lenient Failed vs. Lenient
35 (12.1) 1.17 (0.62–2.24) 1.23 (0.74–2.03) 1.44 (0.78–2.69)
7 (2.3) 2.66 (0.81–8.73) 1.08 (0.34–3.39) 2.86 (0.96–8.54)
2 (0.7)
1 (0.3)
4 (1.3)
10 (3.5) 2.24 (0.65–7.73) 0.74 (0.25–2.18) 1.67 (0.57–4.88)
4 (1.6) 0.83 (0.22–3.14) 3.01 (0.91–10.02) 2.51 (0.56–11.23)
3 (1.3)
1 (0.3)
1 (0.3)
14 (5.0) 0.97 (0.30–3.16) 0.97 (0.42–2.25) 0.95 (0.31–2.88)
0
14 (5.0)
3 (1.0)
3 (1.0)
0
0
2 (0.8)
15 (5.0)
ient, component events include all such events. Outcome event in the successful strict and failed
ient rate control group the outcome events were analyzed from 9 days, the mean duration of the
ears of follow-up was determined with use of the Kaplan-Meier curves. †Death from any cause isonenand I
te L
ach pat
the len
e at 3 yValues are n (%).
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would have had a heart rate 100 beats/min (13). The
ACE II study was not designed to assess differences
etween successful strict, failed strict, and lenient rate
ontrol; therefore the current study is underpowered for this
Figure 3 Quality of Life During Study
Outcome of The Medical Outcome Study Short Form-36 (SF-36), Multidimensional
and University of Toronto AF Severity Scale (AF severity scale) at baseline and endnalysis. Follow-up was limited to 3 years.Conclusions
There is no difference in outcome between successful and
failed strict rate control. Strict rate control seems to have no
favorable effect in this group of permanent AF patients, not
e Inventory-20 (MFI-20),
dy.Fatigu
of stueven when the heart rate targets are achieved. Therefore,
748 Groenveld et al. JACC Vol. 61, No. 7, 2013
Rate Control Efficacy in Atrial Fibrillation February 19, 2013:741–8lenient rate control might be used as frontline therapy in
patients with permanent AF.
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